Glaxosmithkline Share News (GSK)

UK BROKER RATINGS: Goldman Adds BHP Billiton To Conviction Buy List

UPDATE 1-FDA places Arrowhead Hep B drug on partial hold, shares plunge

(Adds details, background, updates share movement) Jan 12 (Reuters) - Drug developer Arrowhead Research Corp said the U.S. Food and Drug Administration placed the company's experimental hepatitis B treatment on partial clinical hold, seeking additional data from the drug's mid-stage study.

BUZZ-SkyePharma: disappointing sales hit shares

** SkyePharma dives to lowest levels in more than 4 mths on lower-than-expected GlaxoSmithKline Q3 2014 sales of Relvar/Breo Ellipta and Anoro Ellipta, which both use SkyePharma licensed technology [ID: ** Stock, which has had great run over the past year, rising around 200 pct, down 16.5 p

Skyepharma To Meet Expectations But Glaxo Royalties Slower

Ebola Vaccine Trials To Start In Liberia In Late January

Pivotal Ebola vaccine trials to start this month or next -WHO

* Phase III trials set for Guinea, Liberia and Sierra Leone * No major safety issues to date, WHO chief Chan says * Disease has killed more than 8,000 in past year By Stephanie Nebehay GENEVA, Jan 8 (Reuters) - Final-stage trials of experimental Ebola vaccines will begin i

UPDATE 2-Signs Ebola may be levelling off in Sierra Leone - WHO

* Sierra Leone still records 248 new cases in past week * More than 8,000 killed worldwide in epidemic to date * WHO to host meeting on experimental vaccines on Thursday (Adds quotes from UN and WHO officials in Liberia) By Stephanie Nebehay and James Harding Giahyue GEN

UPDATE 3-J&J, Bavarian Nordic start clinical tests in Ebola vaccine race

* Initial Phase I clinical study starts in Britain * First tests in Britain, more planned in U.S. and Africa * J&J expects to have 2 million courses available in 2015 * Vaccine uses "prime-boost" approach involving two shots * Bavarian Nordic shares hit highest level in fo

J&J and Bavarian Nordic start clinical tests of Ebola vaccine

LONDON, Jan 6 (Reuters) - U.S. drugmaker Johnson & Johnson said on Tuesday it had started clinical trials of its experimental Ebola vaccine, which uses a booster developed by Denmark's Bavarian Nordic. The initiation of the Phase I tests, which had been expected about now, marks further pr

London midday: Resource stocks drag FTSE 100 into the red

UK stocks were trading firmly in the red by Monday lunchtime despite a positive start, with shares in the oil and mining sectors providing a drag. London's FTSE 100 was down 0.9% at 6,489 by midday, dropping sharply after reaching a high of 6,576.74 early on. This week will be the first full tradin

London open: UK stocks rise ahead of data-heavy week, M&S falls

After an initial dip, UK stocks pushed into positive territory early on Monday as traders returned to their desks after the festive holidays in an optimistic mood. London's FTSE 100 index was up 0.4% at 6,571, quickly bouncing off an intraday low of 6,522.59 reached shortly after the open. "This Mo

Britain's top companies to splash out 85 bln stg in dividends-study

* FTSE 350 regular dividends seen up 4.4 pct at 75 bln stg in 2015 * Total payouts seen up 11 pct at 85 bln stg excluding Vodafone * Weak oil price may endanger some energy payouts By Andrew Winterbottom LONDON, Jan 5 (Reuters) - Britain's biggest companies are set to lavi

Ebola crisis could last through 2015 as marks year since outbreak-expert-TRFN

By Belinda Goldsmith LONDON, Dec 24 (Thomson Reuters Foundation) - The Ebola crisis in West Africa that claimed its first victim exactly a year ago is likely to last until the end of 2015, according to a scientist who helped to discover the virus. Two-year-old Emile Ouamouno died in t

NewLink, GSK get U.S. funding for faster development of Ebola vaccines

Dec 23 (Reuters) - The U.S. Department of Health and Human Services (HHS) awarded contracts worth a total of about $43 million to NewLink Genetics Corp and GlaxoSmithKline Plc for faster development of two Ebola vaccines. Under a $30 million contract, NewLink's unit BioProtection Systems Co

Sector movers: Defensive pharma stocks fall as Santa Rally continues

Pharmaceutical and healthcare stocks were leading the fallers on Tuesday as investors dumped defensive assets amid a continued pre-Christmas rally. UK stocks have risen for six straight days as markets rebounded strongly following a recent sell-off. While more cyclical sectors such as construction